Repare Therapeutics Inc.: 10-Q filed 2025-11-14
What Repare Therapeutics Inc. reported in its quarterly report filed 2025-11-14 (fiscal Q3 2025): 35 published measures, 104 facts as tagged in accession 0001193125-25-283336.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-11-14
- Fiscal period
- fiscal Q3 2025
- Accession
- 0001193125-25-283336 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Repare Therapeutics Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 126,747,000 | USD | |
| At 2024-12-31 | 176,506,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 11,620,000 | USD | |
| At 2024-12-31 | 25,375,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 115,127,000 | USD | |
| At 2025-06-30 | 110,408,000 | USD | |
| At 2025-03-31 | 125,097,000 | USD | |
| At 2024-12-31 | 151,131,000 | USD | |
| At 2024-09-30 | 174,959,000 | USD | |
| At 2024-06-30 | 203,677,000 | USD | |
| At 2024-03-31 | 231,953,000 | USD | |
| At 2023-12-31 | 212,082,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 72,825,000 | USD | |
| At 2024-12-31 | 84,717,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 3,258,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -43,529,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -34,406,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -56,018,000 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -42,824,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -49,121,000 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 109,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 541,000 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 30,743,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 17,882,000 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | -461,327,000 | USD | |
| At 2024-12-31 | -417,798,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 42,965,529 | shares | 92 |
| 2025-01-01 to 2025-09-30 | 42,827,767 | shares | 273 |
| 2024-07-01 to 2024-09-30 | 42,452,617 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 42,377,635 | shares | 274 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 43,051,934 | shares | 92 |
| 2025-01-01 to 2025-09-30 | 42,827,767 | shares | 273 |
| 2024-07-01 to 2024-09-30 | 42,452,617 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 42,377,635 | shares | 274 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 0.08 | USD/shares | 92 |
| 2025-01-01 to 2025-09-30 | -1.02 | USD/shares | 273 |
| 2024-07-01 to 2024-09-30 | -0.81 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | -1.32 | USD/shares | 274 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 0.08 | USD/shares | 92 |
| 2025-01-01 to 2025-09-30 | -1.02 | USD/shares | 273 |
| 2024-07-01 to 2024-09-30 | -0.81 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | -1.32 | USD/shares | 274 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 145,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 763,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 485,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 1,440,000 | USD | 274 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 0 | USD | |
| At 2024-12-31 | 2,294,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 7,456,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 18,242,000 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 1,131,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -47,836,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -36,372,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -62,875,000 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 124,426,000 | USD | |
| At 2024-12-31 | 171,149,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 11,620,000 | USD | |
| At 2024-12-31 | 25,287,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 1,334,000 | USD | |
| At 2024-12-31 | 3,623,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 13,876,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 68,759,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 36,372,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 116,352,000 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 7,502,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 42,055,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 28,401,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 91,446,000 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 42,985,755 | shares | |
| At 2024-12-31 | 42,510,708 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 14,000 | USD | |
| At 2024-12-31 | 54,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 0 | USD | |
| At 2024-12-31 | 1,924,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 600,000 | USD | |
| At 2024-12-31 | 179,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 3,403,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -42,766,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -33,921,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -54,578,000 | USD | 274 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -43,529,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -56,018,000 | USD | 274 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 3,280,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -43,569,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -34,132,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -55,906,000 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 4,548,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 18,229,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 6,444,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 23,379,000 | USD | 274 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 2,294,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 1,467,000 | USD | 274 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 89,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 49,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -42,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -95,000 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 2,272,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 5,070,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 2,451,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 8,297,000 | USD | 274 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 1,335,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 1,837,000 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -2,285,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 8,256,000 | USD | 274 |
Inspect the source
- Entity
- Repare Therapeutics Inc. / CIK 0001808158
- Captured
- 2026-09-21T17:28:08.273Z
- SEC response SHA-256
5b4ad4b22a3a13ec8dc2fdffd62cba7c92ae43dbdaef148f3fb71bd1d83755c6
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001808158.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))